Share This Author
The Diabetes Excess Weight Loss (DEWL) Trial: a randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes
In a ‘real-world’ setting, prescription of an energy-reduced low-fat diet, with either increased protein or carbohydrate, results in similar modest losses in weight and waist circumference over 2 years.
Opportunistic screening for familial hypercholesterolaemia via a community laboratory
The community laboratory is well placed to screen opportunistically for subjects with potential hypercholesterolaemia, and may be achieved using either the MED-PED criteria or a serum LDL-cholesterol cut-off point of ≥6.5 mmol/L, irrespective of age.
Improvements in Glucose Metabolism and Insulin Sensitivity with a Low-Carbohydrate Diet in Obese Patients with Type 2 Diabetes
A low-carbohydrate, high-fat diet with detailed physiological assessments of insulin sensitivity, glycemic control, and risk factors for cardiovascular disease was well tolerated and achieved weight loss over 24 weeks in subjects with diabetes.
Implementation of a successful lifestyle intervention programme for New Zealand Maori to reduce the risk of type 2 diabetes and cardiovascular disease.
This approach successfully reduced risk for type 2 diabetes and cardiovascular disease in New Zealand Maori in the short term.
Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia.
Genetic analysis of familial hypercholesterolaemia in Western Australia.
Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit.
Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia.
Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia.
Mipomersen, an antisense apolipoprotein B synthesis inhibitor
- D. Bell, A. Hooper, J. Burnett
- Medicine, BiologyExpert Opinion on Investigational Drugs
- 16 January 2011
An understanding of the pharmacokinetic and pharmacodynamic characteristics of mipomersen and insight into its clinical efficacy and safety is provided and shows promise as an adjunctive agent by reducing apoB-containing lipoproteins in patients at high risk of atherosclerotic cardiovascular disease who are not at target or are intolerant of statins.